ProSomnus Reports First Quarter 2023 Financial Results
Recent Business Highlights
- Generated year-over year revenue growth of 55% reflecting revenues of
$5.8 million for the first quarter compared to$3.7 million during the first quarter of 2022, and in line with strong revenues in the fourth quarter of 2022. - Continued traction on strategic growth initiatives, including direct sales team expansion in the U.S. and Europe, advancing our next generation device with remote patient monitoring capability toward commercial introduction during late 2023 and the continued generation of clinical data.
- Commenced enrollment in the Severe Obstructive Sleep Apnea (SOS) labeling expansion study, with five centers activated and on track to complete enrollment in 2023.
- Successfully moved to our new headquarters and manufacturing center of excellence. The move quintupled our potential manufacturing capacity, positioning ProSomnus to be able to meet the rapidly growing demand for the company’s precision intraoral medical devices.
- Expanded the Company’s patent portfolio by securing two additional patents covering its digital manufacturing and iterative titration technologies.
“ProSomnus delivered strong operational results and made healthy strategic progress during our first full quarter as a public company,” said
Financial Results for the First Quarter of 2023
Revenue for the three-month period and year ended
Gross margin finished at 53% for the three-month period ended
Sales and marketing expenses increased by
Research and development expenses increased by
General and administrative expenses increased by
Total other income (expense) totaled an expense of
On
Conference Call and Webcast Information
The Company will host a conference call to discuss its first quarter 2023 financial results today,
About ProSomnus
ProSomnus (NASDAQ: OSA) precision intraoral medical devices offer effective, economical, and patient-preferred treatment for patients suffering from Obstructive Sleep Apnea (OSA). ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices to treat OSA, which affects over 74 million people in
Important Notice Regarding Forward-Looking Statements
This Press Release contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E the Securities Exchange Act of 1934, both as amended. Statements that are not historical facts, including statements regarding ProSomnus’s labeling expansion, its future growth and expenses, and the growing markets for its devices, are forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,” “will,” “potential,” “projects,” “predicts,” “continue,” or “should,” or, in each case, their negative or other variations or comparable terminology. The forward-looking statements contained in this report are based on our current expectations and beliefs concerning future developments and their potential effects on us. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.
Such risks and uncertainties include, but are not limited to: (i) risk related to being unable to comply with its debt covenants or successfully renegotiate such covenants; (ii) the risk of potential future significant dilution to stockholders resulting from lender conversions under the convertible debt financing; (iii) uncertainty of the projected financial information with respect to ProSomnus; (iv) ProSomnus’s limited operating history and history of losses; (v) the roll-out of ProSomnus’s business and the timing of expected business milestones; (vi) the understanding and adoption by dentists and other healthcare professionals of ProSomnus oral devices for mild-to-moderate OSA; (vii) expectations concerning the effectiveness of OSA treatment using ProSomnus oral devices and the potential for patient relapse after completion of treatment; (viii) ProSomnus’s ability to maintain and grow its profit margin from sales of ProSomnus oral devices; (ix) ProSomnus’s ability to formulate, implement and modify as necessary effective sales, marketing, and strategic initiatives to drive revenue growth; (x) ProSomnus’s ability to expand internationally; (xi) the viability of ProSomnus’s intellectual property and intellectual property created in the future; (xii) government regulations and ProSomnus’s ability to obtain applicable regulatory approvals and comply with government regulations, including under healthcare laws and the rules and regulations of the U.S. Food and Drug Administration; (xiii) the risk of downturns in the market and ProSomnus’s industry including, but not limited to, as a result of the COVID-19 pandemic; and (xiv) the outcome of any legal proceedings that may be instituted against ProSomnus. A further list and description of risks and uncertainties can be found in ProSomnus’s annual reports on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) any subsequently filed quarterly reports on Form 10-Q, and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Forward-looking statements do not represent our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements.
| PROSOMNUS, INC. | |||||||||||||
| UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||
| Three-month period ended | |||||||||||||
| 2023 | 2022 | 2022 | |||||||||||
| Revenue | $ | 5,808,380 | $ | 5,792,312 | $ | 3,743,143 | |||||||
| Cost of revenue | 2,756,631 | 2,686,863 | 1,578,496 | ||||||||||
| Gross profit | 3,051,749 | 3,105,449 | 2,164,647 | ||||||||||
| Operating expenses | |||||||||||||
| Sales and marketing | 2,824,048 | 2,415,155 | 2,117,419 | ||||||||||
| Research and development | 1,018,969 | 1,065,750 | 557,633 | ||||||||||
| General and administrative | 3,353,007 | 5,674,961 | 1,353,735 | ||||||||||
| Total operating expenses | 7,196,024 | 9,155,866 | 4,028,787 | ||||||||||
| Loss from operations | (4,144,275 | ) | (6,050,417 | ) | (1,864,140 | ) | |||||||
| Other income (expense) | |||||||||||||
| Interest expense | (1,171,810 | ) | (2,405,029 | ) | (1,095,837 | ) | |||||||
| Change in fair value of earnout liability | 1,500,000 | 9,260,000 | - | ||||||||||
| Change in fair value of debt | (1,827,000 | ) | 553,235 | - | |||||||||
| Change in fair value of warrant liability | (842,559 | ) | 3,255,342 | (20,756 | ) | ||||||||
| Other | (406,527 | ) | - | - | |||||||||
| Loss on extinguishment of debt | - | (2,405,111 | ) | - | |||||||||
| Total other income (expense) | (2,747,896 | ) | 8,258,437 | (1,116,593 | ) | ||||||||
| Net loss | $ | (6,892,171 | ) | $ | 2,208,020 | $ | (2,980,733 | ) | |||||
| PROSOMNUS, INC. | ||||||||
| UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| 2023 | 2022 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 11,560,319 | $ | 15,916,141 | ||||
| Accounts receivable, net | 2,662,752 | 2,843,148 | ||||||
| Inventory | 758,188 | 639,945 | ||||||
| Prepaid expenses and other current assets | 1,571,197 | 1,846,870 | ||||||
| Total current assets | 16,552,456 | 21,246,104 | ||||||
| Property and equipment, net | 2,994,769 | 2,404,402 | ||||||
| Right-of-use assets, net | 8,775,016 | 9,283,222 | ||||||
| Other assets | 262,913 | 262,913 | ||||||
| Total assets | $ | 28,585,154 | $ | 33,196,641 | ||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,309,656 | $ | 2,101,572 | ||||
| Accrued Expenses | 4,906,746 | 3,706,094 | ||||||
| Equipment financing obligation | 57,839 | 58,973 | ||||||
| Finance lease liabilities | 898,027 | 1,008,587 | ||||||
| Operating lease liabilities | 329,767 | 215,043 | ||||||
| Total current liabilities | 7,502,035 | 7,090,269 | ||||||
| Equipment financing obligation, net of current portion | 171,984 | 185,645 | ||||||
| Finance lease liabilities, net of current portion | 1,917,877 | 2,081,410 | ||||||
| Operating lease liabilities, net of current portion | 5,452,282 | 5,525,562 | ||||||
| Senior Convertible notes | 14,478,000 | 13,651,000 | ||||||
| Subordinated Convertible note | 12,079,380 | 10,355,681 | ||||||
| Earnout Liability | 11,310,000 | 12,810,000 | ||||||
| Warrant liability | 2,834,062 | 1,991,503 | ||||||
| Total liabilities | 55,745,620 | 53,691,070 | ||||||
| Stockholders’ deficit: | ||||||||
| Common stock (16,041,464 shares issued and outstanding at |
1,604 | 1,604 | ||||||
| Additional paid-in capital | 190,524,696 | 190,298,562 | ||||||
| Accumulated deficit | (217,686,766 | ) | (210,794,595 | ) | ||||
| Total stockholders’ deficit | (27,160,466 | ) | (20,494,429 | ) | ||||
| Total liabilities and stockholders’ deficit | $ | 28,585,154 | $ | 33,196,641 | ||||
Investor Contact
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com
Media Contact
ICR Westwicke
Phone: +1.646.866.4012
Email: Sean.Leous@westwicke.com
Source: ProSomnus Sleep Technologies, Inc.